GlassScriptPhysician profile
Juan G Flores
NPI 1093931909
$91,309.92
in general payments reported to CMS, 2019-2025
19 companies · $90K in 2025
The $90K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $11.56 · 2021: $51.48 · 2022: $701 · 2023: $239 · 2024: $318 · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $8,221 · Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,100.00 |
| Travel and Lodging | $8,221.46 |
| Food and Beverage | $1,740.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $89,221.03 | 2025 | Zepbound, Mounjaro |
| Zimmer Biomet Holdings, INC. | $611.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $158.30 | 2019-2020 | |
| Aspira Women'S Health INC | $151.84 | 2024 | Ova1 |
| Kerecis Limited | $144.10 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Conmed Corporation | $138.05 | 2024 | Airseal |
| Novo Nordisk INC | $121.87 | 2019 | |
| Resmed Corp | $120.00 | 2019 | |
| Hemosonics LLC | $118.07 | 2023 | Quantra Qplus System |
| Verona Pharma, INC. | $117.31 | 2025 | Ohtuvayre |
| Atricure, INC. | $90.58 | 2023 | |
| La Jolla Pharmaceutical Company | $90.08 | 2022 | |
| Genentech USA, INC. | $79.90 | 2019 | |
| Csl Behring | $36.61 | 2021 | |
| Edwards Lifesciences Corporation | $30.46 | 2023 | Sapien 3 Ultra Resilia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $27.67 | 2024 | |
| Stryker Corporation | $22.71 | 2025 | Na |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.39 | 2019 | |
| Glaxosmithkline, LLC. | $14.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.